newsfilter
← Earnings
Earnings Releases·

Ironwood Pharmaceuticals — Q3 2026 Earnings Summary

  • Q3 2026 total revenue rose to $133.0 million from $122.1 million in Q3 2025, while GAAP net income increased to $59.8 million ($0.36/share) from $40.1 million ($0.25/share), and Adjusted EBITDA grew to $97.9 million from $81.8 million.
  • Full-year 2026 guidance was raised across the board: U.S. LINZESS net sales to $1.20–$1.25 billion, total revenue to $485–$510 million, and Adjusted EBITDA to over $350 million, driven by improved net pricing and mid-single-digit prescription demand growth.
  • Strategic leadership transition announced with Chief Commercial Officer Tammi Gaskins set to succeed CEO Tom McCourt as CEO and join the Board effective January 1, 2027, while McCourt retires but remains on the Board.
  • Apraglutide development remains on track for a 2029 regulatory filing subject to STARS-2 trial results, with over 100 sites in 22 countries planned for activation, while the company repaid $60.0 million on its revolving credit facility.
Company
IRONWOOD PHARMACEUTICALS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic